The FDA has given an early Christmas present to AstraZeneca and Daiichi Sankyo by approving their DS-8201 for HER2-positive breast cancer well ahead of schedule. The US regulator has cleared the HER2 ...

ENHERTU (formerly known as DS-8201; trastuzumab deruxtecan outside the U.S.; fam-trastuzumab deruxtecan-nxki in the U.S. only) has been approved for use only in the U.S. and Japan. ENHERTU has not ...

ENHERTU (HER2 ADC) Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2 low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: ...

U3-1402 and DS-8201, now approved as Enhertu in breast cancer and the center of a multibillion-dollar tie-up with AstraZeneca. The CRO and pharma, which have collaborated in separate areas in the ...

Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s ENHERTU that showed clinically meaningful responses across a broad range of tumors ENHERTU now has five approved indications ...

You can reach Adam on Signal at stataf.54. CHICAGO — The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but previously ...

Cancer drug history was made last Friday. Enhertu, the blockbuster antibody-drug conjugate discovered by Daiichi Sankyo and co-developed by AstraZeneca, was approved in the U.S. to treat any ...

TOKYO & BASKING RIDGE, N.J., May 31, 2025--ENHERTU Reduced Risk of Death by 30% as 2L Therapy in Patients w/HER2+ Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial ...

CFO Koji Ogawa highlighted that ENHERTU sales grew by ¥128.4 billion ... Fumiyoshi Sakai, UBS, raised questions on T-cell Engager DS-2243’s unique modality and target applications.

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

AstraZeneca's blockbuster breast cancer drug Enhertu will be added to China's state-run health insurance scheme from Jan. 1, according to an update from the National Healthcare Security ...